{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:45:59Z","timestamp":1791809159148,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.apjo.2026.100278","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:28:33Z","timestamp":1767918513000},"page":"100278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intravitreal aflibercept 8\u202fmg versus 2\u202fmg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1585","authenticated-orcid":false,"given":"Andrew","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6428","authenticated-orcid":false,"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-7895","authenticated-orcid":false,"given":"Andrea","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula Maria","family":"Schmidt-Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0673-012X","authenticated-orcid":false,"given":"Zoran","family":"Hasanbasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1578","authenticated-orcid":false,"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2026.100278_bib1","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.apjo.2026.100278_bib2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.apjo.2026.100278_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100278_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2026.100278_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajo.2014.05.004","article-title":"Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients: multicenter diagnosis with multimodal imaging","volume":"158","author":"Coscas","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100278_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajo.2022.07.024","article-title":"Polypoidal choroidal vasculopathy based on non-ICGA criteria in White patients with neovascular age-related macular degeneration","volume":"244","author":"Chaikitmongkol","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2021.08.006","article-title":"Multimodal imaging comparison of polypoidal choroidal vasculopathy between Asian and Caucasian populations","volume":"234","author":"Corvi","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib10","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1007\/s00417-021-05451-2","article-title":"Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is ours","volume":"259","author":"Lanzetta","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.apjo.2026.100278_bib12","first-page":"1465","article-title":"Anti-vascular endothelial growth factor biosimilars for macular degeneration","author":"Sunaga","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apjo.2026.100278_bib13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100278_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.11648\/j.ijovs.20210603.13","article-title":"Treatment burden and quality of life of patients with neovascular age-related macular degeneration (nAMD) and their caregivers\u2014a review","volume":"6","author":"Biswas","year":"2021","journal-title":"Int J Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100278_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/APO.0000000000000391","article-title":"Challenges in eye care in the Asia-Pacific region","volume":"10","author":"Yusufu","year":"2021","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1755-3768.2009.01843.x","article-title":"EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"88","author":"Tano","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00417-012-1970-3","article-title":"EXTEND III: efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD","volume":"250","author":"Kwon","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40259-014-0106-1","article-title":"EXTEND II: an open-label phase III multicentre study to evaluate efficacy and safety of ranibizumab in Chinese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"28","author":"Zhao","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.apjo.2026.100278_bib19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/IAE.0000000000001986","article-title":"Efficacy and safety of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration: subgroup analyses from the VIEW trials","volume":"39","author":"Wong","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100278_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.jfma.2022.02.005","article-title":"Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan - results from the 12-month, observational RENOWNED study","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.apjo.2026.100278_bib22","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials","volume":"261","author":"Takahashi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib23","unstructured":"Bayer.Eylea HD (Aflibercept) injection 8 mg approved by FDA for treatment of wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Availabe from \u3008https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/eylea-hd-aflibercept-injection-8-mg-approved-fda-treatment-wet\u3009."},{"key":"10.1016\/j.apjo.2026.100278_bib24","unstructured":"Hayes H.EMA recommends approval of high-dose intravitreal aflibercept (Eylea\u00ae) 8mg for nAMD and macular oedema. Availabe from \u3008https:\/\/europe.ophthalmologytimes.com\/view\/ema-recommends-approval-of-high-dose-intravitreal-aflibercept-eylea-8mg-for-namd-and-macular-oedema\u3009."},{"key":"10.1016\/j.apjo.2026.100278_bib25","unstructured":"Bayer. Eylea 8 mg approved in China for wet age-related macular degeneration. Available from (https:\/\/www.bayer.com\/media\/en-us\/eylea-8-mg-approved-in-china-for-wet-age-related-macular-degeneration\/)."},{"key":"10.1016\/j.apjo.2026.100278_bib26","unstructured":"Bayer. New Eylea\u2122 8 mg approved in Japan. Available from: (https:\/\/www.bayer.com\/media\/en-us\/new-eylea-8-mg-approved-in-japan\/)."},{"key":"10.1016\/j.apjo.2026.100278_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2026.100278_bib28","first-page":"5","article-title":"Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision","volume":"39","author":"Shona","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100278_bib30","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1111\/aos.13751","article-title":"Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies","volume":"96","author":"Lanzetta","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12886-023-02780-0","article-title":"Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis","volume":"23","author":"Tsai","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib32","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/IAE.0000000000002624","article-title":"Real-world effectiveness and safety of ranibizumab treatment in patients with and without polypoidal choroidal vasculopathy: twelve-month results from the LUMINOUS study","volume":"40","author":"Koh","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.apjo.2026.100278_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.oret.2020.07.003","article-title":"Outcomes by baseline choroidal neovascularization features in age-related macular degeneration: a post hoc analysis of the VIEW studies","volume":"5","author":"Steinle","year":"2021","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100278_bib34","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1111\/aos.15149","article-title":"Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up","volume":"100","author":"Park","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100278_bib35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:41:15Z","timestamp":1780062075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2162098926000046"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100278","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal aflibercept 8\u202fmg versus 2\u202fmg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100278"}}